Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension
CARDIOLOGY IN THE YOUNG, cilt.28, sa.4, ss.542-547, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 28 Sayı: 4
- Basım Tarihi: 2018
- Doi Numarası: 10.1017/s1047951117002542
- Dergi Adı: CARDIOLOGY IN THE YOUNG
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.542-547
- Hacettepe Üniversitesi Adresli: Evet
Özet
Background Macitentan is an orally active, potent, dual endothelin receptor antagonist and is the only registered treatment for pulmonary arterial hypertension that significantly reduced morbidity and mortality in a long-term event-driven study.